(PharmaNewsWire.Com, June 19, 2021 ) The report “Breast Reconstruction Market by Product (Breast implant (Silicone, Saline), Tissue Expander, Acellular Dermal Matrix), Procedure (Immediate, Delayed, Revision), Type (Unilateral, Bilateral), End User (Hospital, Cosmetology Clinics) – Global Forecast to 2025″, is projected to reach USD 603 million by 2025 from USD 430 million in 2020, at a CAGR of 7.0% from 2020 to 2025.
The rising incidence of breast cancer and the availability of reimbursement for breast reconstruction are major driving factors for the market. Moreover, the development of 3D-printed breast implants is expected to offer significant growth opportunities to market players in the coming years.
Recent Developments:
- In 2019, Polytech Health & Aesthetics received US FDA approval for its textured breast implants (macrotextured and polyurethane-coated implants)
- In 2018, J&J launched CPX4 breast tissue expander
- In 2018, Polytech Health & Aesthetics merged with G&G Biotechnology
Based on the product, segmented into breast implants, tissue expanders, and acellular dermal matrix. The breast implants segment accounted for the largest market share in 2019.
Based on the procedure, the breast reconstruction market is segmented into immediate, delayed, and revision procedures. The immediate procedures segment accounted for the largest market share in 2019. This is primarily attributed to the increasing number of surgeries post-mastectomy and rising awareness.
Based on type, segmented into unilateral and bilateral. The unilateral segment accounted for the largest market share in 2019. The increasing incidence of breast cancer and rising awareness are major factors responsible for the dominant share of this segment.
Geographical View in-detailed:
The breast reconstruction market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America held the largest share of the market, followed by Europe. The rising incidences of breast cancer, increasing awareness of breast reconstruction, and FDA approvals for breast reconstruction products in this region are the major factors driving the growth of the breast reconstruction in North America.
The prominent players operating in the global breast reconstruction market are Johnson & Johnson (US), Allergan (Ireland), Ideal Implant Incorporated (US), Sebbin (France), GC Aesthetics (Ireland), Polytech Health & Aesthetics (Germany), Sientra (US), Integra Lifesciences (US), RTI Surgical Holdings (US), Establishment Labs S.A. (Costa Rica), and Silimed (Brazil).
Johnson and Johnson (US) is the dominant player in the breast reconstruction market. The company has a strong portfolio of breast reconstruction products. It has established a significant footprint in Europe, Asia, and Latin, South, & North America. It focuses on organic and inorganic strategies such as product launches. The company operates in this market through Mentor, which it acquired in January 2009. J&J has a strong presence in over 60 countries and a wide network of subsidiaries across the globe. It recently launched a new warranty program for all MENTOR breast implants sold in the US.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
